Biomanufacturing Services

Just-Evotec Biologics produces biopharmaceutical drug substance for its clients to support early-phase and late-phase clinical trials with its continuous manufacturing platform. Our experts are experienced in the conversion of existing fed-batch processes to our platform irrespective of the clinical stage. Our J.POD biomanufacturing facilities are designed to deliver biologics drug substance for first-in-human clinical trials all the way through to commercial production.

Our unique continuous manufacturing platform technology can de-risk supply by producing huge quantities of antibody mass in fewer batches and at smaller scale than traditional batch manufacturing. This allows our partners to save time, energy, and resources all along the path to commercialization.
Kevin Ingham, Manufacturing Operations and Site Head, Redmond, US

Early-Stage Clinical Supply

We manufacture antibody and antibody-related biotherapeutics for first-in-human and early-stage clinical trials in our continuous manufacturing platform. Performing early-stage clinical manufacturing with a continuous bioprocess allows partners to avoid switching from fed-batch to continuous production during their clinical journey and allows them to take advantage of lower cost of goods, greater agility and lower risk during late-stage development.

Late-Stage Clinical & Ph III Supply

We possess the capability to provide support for late-stage clinical programs, regardless of whether an intensified process has been developed beforehand. By leveraging existing cell lines and transitioning from fed-batch to perfusion and fully continuous modes, we mitigate the scaling-up risks while reaping the benefits of lower commercial COGS and a more adaptable supply chain.

Commercial Supply for Marketed Products

Existing commercial biotherapeutic products currently manufactured with a fed-batch process may be facing low productivity/high COGS challenges which can also be correlated to supply chain bottlenecks. We can develop intensified and fully continuous process for existing commercial molecules facing a COGS challenge or requiring larger supply capacity.

Continuous manufacturing emerges as the ideal solution for molecules, especially those with uncertain future indications or potentially facing increasing mass demand over time, offering unparalleled flexibility to meet evolving needs.

Philip Boehme

Philip Boehme

EVP Partnering & Transformation

vCard
Logo Just white
Just – Evotec Biologics is a mission-driven Business Unit of Evotec with the aim of radically improving access to biologics through a de-risked, agile approach, coupled with significantly lower manufacturing cost. Over the years we have advanced an industry-transforming bioprocessing platform, which we leverage with our partners to drive what we call the paradigm shift in biologics.